Treatment | Genotype | Eosinophils |
---|
PBS | B10.RIII | 0.5 % |
| IFN-β-/- | 0.7 % |
OVA | B10.RIII | 55 % |
| IFN-β-/- | 62 % |
OVA+CPG 5 μ | B10.RIII | 2.1 % |
| IFN-β-/- | 9.2 % |
OVA+CPG 10 μ | B10.RIII | 1. 9 % |
| IFN-β-/- | 9.4 % |
OVA+CPG 20 μ | B10.RIII | 1.9 % |
| IFN-β-/- | 9.0 % |
- B10.RIII/WT (□) and IFN-β-/- (■) mice were sensitized to OVA by intraperitoneal injection and subsequently challenged with OVA either alone or with different dose of CpG-ODN by intranasal drops on days 14 and 16. Eosinophil percentage in bronchoalveolar lavage with different dose of intranasal CpG-ODN were similar in all IFN-β-/- treated mice.